Navigation Links
Interleukin Genetics to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
Date:5/13/2008

WALTHAM, Mass., May 13 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI) announced today that Lewis H. Bender, Chief Executive Officer, will present at the Rodman and Renshaw 5th Annual Global Healthcare Conference on Monday May 19, 2008, at 10:00 a.m. CEST (4:00 a.m. EDT). The conference will be held at Le Meridien Beach Plaza Hotel, Monte Carlo, Monaco.

A live audio webcast of the presentation will be available on the Investors section of the Company's website, http://www.ilgenetics.com. A replay of the presentation will be available on the Interleukin Genetics website for 14 days following the presentation.

About Interleukin Genetics

Interleukin Genetics, Inc. (Amex: ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers, and has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. Interleukin is headquartered in Waltham, MA. For more information about Interle
'/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Interleukin Genetics Announces Management and Board Appointments
2. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
3. Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results
4. Interleukin Genetics Announces Conversion of $2.04 Million of Debt Into Common Stock
5. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
6. Interleukin Genetics Retains Top Life Science Communications Firms
7. Interleukin Genetics Announces Conference Call and Webcast to Discuss Fourth Quarter and Year End 2007 Business Results
8. Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer
9. Interleukin Genetics Announces Conference Call and Webcast to Discuss First Quarter 2008 Business Results
10. Digital Unions RT1(TM) Software Creates Telegenetics Network for Region 3 Genetics Collaborative
11. Response Genetics Reports Second Quarter 2007 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)...l temperatures and energy costs continue to soar, ...inable future. An attractive replacement for gas...ine in Genome Research ( www.genome.org ), scien...hanol-producing microorganisms, uncovering genetic...hnologies needed to implement production on a glob...
(Date:11/6/2009)...6 Helix BioPharma Corp. ...nced that John Docherty, president and chief opera...,s 6th annual Investor Summit on November 10, 2009... Mr. Docherty will provide an overview of the Com...7 and Topical Interferon Alpha-2b. The slide show...
(Date:11/6/2009)...swire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ON...day announced updated results from a Phase II stud...omas metastatic to the lung in a poster presentati...ociety Meeting held in Miami Beach, Florida, from ...tled "A Phase II Study of Intravenous REOLYSIN (Wi...
(Date:11/5/2009).... 5 The endangered black-footed fe.... This rare carnivore feeds on prairie dogs. Th...often entire population die-offs in towns occur. ...lemented a ferret breeding program and has been re...ly native habitat. Unfortunately, plague can swee...
Breaking Biology Technology:Genomes of biofuel yeasts reveal clues that could boost fuel ethanol production worldwide 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 3Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2
Miller Brewing selects Procuri software
...enter business of Telstar Communications, Inc. o... of Minneapolis, in a deal that closed Aug. 25, th...is an application and systems integration company,...aging, contact center and IP telephony systems. , ...upaca Telephone and evolved into Telstar. It is an...
...sin Alumni Research Foundation has reached an out...gy firm IBM over charges of patent infringement,...fringing on patented technology by marketing and s...at are based on WARF,s technology. A trial was sch...oth sides are happy with the agreement," WARF spok...
Other Biology Technology:WARF settles patent dispute with IBM 2
(Date:11/9/2009)...logists have had their hands tied because more tha...sable a protein called p53. As a critical anti-can...ing operations within cells. When cells lose p53, ...ed. , These tumors might be tough, but they,re ...ing Harbor Laboratory (CSHL). The chink in the tum...
(Date:11/9/2009)...wings has inspired a 3.2m, three-year research pro...elds of security, energy and the environment. The ...company QinetiQ have just signed a collaborative c...dbreaking physical sciences research. , Over th...niversity of Exeter and QinetiQ will work together...
(Date:11/9/2009)...9 A nutritionist whose research was instrumental ...en, Infants and Children (WIC) food subsidy will r...outstanding achievement in the field of maternal-f... a professor in the Department of Community Health...eles School of Public Health, will receive the awa...
Breaking Biology News(10 mins):CSHL study shows that some malignant tumors can be shut down after all 2CSHL study shows that some malignant tumors can be shut down after all 3£3.2m ($5.4 million) research project to capture brilliance of butterfly wings 2March of Dimes honors Dr. Gail Harrison for outstanding work in maternal-fetal nutrition 2Covance to Present at William Blair 26 Companys 29th Annual Growth Stock Conference 48178 1Companion Global Healthcare Inc Offers Additional Hospital Choices to Employers Individuals Looking to Save on Fully Credentialed Health Care 48175 1Companion Global Healthcare Inc Offers Additional Hospital Choices to Employers Individuals Looking to Save on Fully Credentialed Health Care 48175 2CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement 12522 1CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement 12522 2CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement 12522 3
...essor of biology in Arts & Sciences, has made a br...eolar dominance, the silencing of an entire parent... animal. , Since the machinery involved in nucl... can go haywire in diseases such as cancer, Pikaar...nt implications for applied medical research. , ...
...onefish from Miami down to the Marquesas Islands, ... down slightly from the average of previous census...e who are counting, researchers speculate. The Uni... Atmospheric Science held the sixth annual Florida...servation group Bonefish & Tarpon Unlimited (BTU),...
...ting of skeletal muscle, chronic inflammation of t...bs can result in significant physical impairment....y and community health professor Kimberly Huey, pa...properties of Vitamin E may be associated with red...nes, in vitro, in various types of cells. Cytokine...
Other Biology News:Researchers solve piece of large-scale gene silencing mystery 2Researchers solve piece of large-scale gene silencing mystery 3Researchers solve piece of large-scale gene silencing mystery 4Bonefish census reveals population holding steady 2Vitamin E shows possible promise in easing chronic inflammation 2Vitamin E shows possible promise in easing chronic inflammation 3
Anti-IL-12 / IL-23 Monoclonal Antibody, Alexa Fluor 647 Conjugated, Clone C17.8 from eBioscience
Mouse Anti-IFN-g / CD69 / CD4 / CD3 BDFastImmune Antibody, APC, PerCP-Cy5.5, PE, FITC Conjugated from BD Biosciences - Immunocytometry Systems
Mouse Anti-Transferrin, N-terminus Monoclonal Antibody, Unconjugated, Clone 236-18241 from Meridian Life Science, Inc.
Rabbit Anti-Phosphothreonine-X-Phosphotyrosine Polyclonal Antibody, Horseradish Peroxidase Conjugated from Abcam
Biology Products: